Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAH244 (CD33/CD123 CAR-T) in R/R AML
NCT06420063Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute myeloid leukemia (AML), sponsored by Essen BioTech. Primary endpoint: Incidence and severity of dose-limiting toxicities at 28 days. Started Jul 2024; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06420063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06420063.